CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

1.34
-0.01  -1%
Previous Close 1.35
Open 1.33
Price To Book 1.65
Market Cap 11,613,332
Shares 8,666,666
Volume 375,521
Short Ratio 0.24
Av. Daily Volume 1,024,598
Stock charts supplied by TradingView

NewsSee all news

  1. Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update

    Piclidenoson has been submitted for the treatment of coronavirus under compassionate use program in Israel Top-line data from Phase II Namodenoson trial for NASH expected during April 2020 Interim results from

  2. Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel

    Rationale: Anti-Rheumatic and Ant-Viral Effects with Excellent Safety Profile Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address

  3. Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment

    Meetings with prospective partners regarding Piclidenoson as a potential treatment for coronavirus, in addition to established indications for the Company's drugs in Phase II and Phase III studies Can-Fite BioPharma

  4. Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson

    Results indicate Namodenoson has a good safety profile and is well tolerated in patients under compassionate use Two patients from the former Phase II study are still undergoing treatment of Namodenoson, each with an

  5. Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University

    Can-Fite to Support Research Directed by Kamel Khalili, Ph.D. on Piclidenoson against Coronaviruses Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
Piclidenoson (CF101)
Glaucoma
Phase 2 data did not meet primary endpoint - March 27, 2019. Phase 3 trial to be initiated 2H 2020.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 interim analysis due 4Q 2020.
Piclidenoson (CF101)
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 trial initiation announced August 2018 continues to enrol as of August 29, 2019.
Piclidenoson (CF101)
Psoriasis
Phase 2 data due April 2020.
Namodenoson (CF102)
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update

    Piclidenoson has been submitted for the treatment of coronavirus under compassionate use program in Israel Top-line data from Phase II Namodenoson trial for NASH expected during April 2020 Interim results from

  2. Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel

    Rationale: Anti-Rheumatic and Ant-Viral Effects with Excellent Safety Profile Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address

  3. Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment

    Meetings with prospective partners regarding Piclidenoson as a potential treatment for coronavirus, in addition to established indications for the Company's drugs in Phase II and Phase III studies Can-Fite BioPharma

  4. Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson

    Results indicate Namodenoson has a good safety profile and is well tolerated in patients under compassionate use Two patients from the former Phase II study are still undergoing treatment of Namodenoson, each with an

  5. Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University

    Can-Fite to Support Research Directed by Kamel Khalili, Ph.D. on Piclidenoson against Coronaviruses Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small

  6. Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD

    Findings point towards potential weight loss upon utilization of nano molar CBD concentrations Can-Fite experience in this field is based on its Namodenoson drug positioned for NASH; Results from Phase II study of

  7. Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus

    Interim analysis data is expected Q4 2020 Can Fite possesses US patent protecting the anti-viral effects of its two drug candidates and is exploring collaboration to test them against Coronavirus Can-Fite

  8. Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson

    Favorable safety profile is a substantial benefit in the treatment of chronic diseases that require long-term dosing Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of

  9. Pre-clinical Studies Demonstrate CBD's Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement

    In pre-clinical studies, CBD enriched fractions induced anti-liver cancer effect at minute concentrations Expansion of the agreement allows Can-Fite to develop 2 additional clinical indications Can-Fite BioPharma

  10. Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications

    Namodenoson may create powerful combination treatment with checkpoint inhibitors currently on the market Checkpoint inhibitors, including PD-1 and PD-L1 inhibitors, are a novel class of oncology drugs Global market

  11. Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter

    Can Fite has out licensed Namodenoson for the treatment of NASH to CKD in Korea Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that

  12. Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson

    - Can-Fite successfully concluded its End-of-Phase II meeting with the U.S. FDA recently - One Phase III trial for concurrent regulatory approval in U.S. and Europe upon successful study results - Namodenoson has

  13. Can-Fite BioPharma Announces Pricing of $5 Million Public Offering

    PETACH TIKVA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and

  14. Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis

    Interim analysis by IDMC intended to improve study's efficiency and accelerate path towards regulatory approval Piclidenoson evaluated as first line therapy and replacement for the current standard of care,

  15. Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects

    Findings suggest use of cannabinoid-based drugs to treat diseases in which there is an overexpression of A3AR including cancer, autoimmune, inflammatory and metabolic diseases Patent application filed to protect

  16. Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million

    Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the agreement by several

  17. Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer

    Dr. Stemmer, the study principal investigator currently treating liver cancer patients under compassionate use program FDA has agreed recently with the Company on a Phase III study protocol Israeli Society of

  18. Can-Fite CEO Issues Letter to Shareholders

    Q1 2020: Topline results from NASH Phase II study expected Advanced stage clinical pipeline positioned to potentially generate more non-dilutive funding through out-licensing distribution agreements Two Phase III

  19. New Data From Hadassah Medical Center Lab Show Can-Fite's Namodenoson Induces Weight Loss

    Findings combined with Namodenoson's good safety profile support its potential utilization as an anti-obesity drug PCT Patent application filed for anti-obesity indication Results from Phase II study of

  20. Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing

    Golan Bitton will contribute his skills acquired through long service in Israeli Ministry of Defense and founder of Univo Pharmaceuticals Can-Fite platform technology enables screening of cannabis derived products

  21. Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial

    Psoriasis therapeutic market estimated to reach $11.4B in 2020 Distribution deals for the psoriasis indication are in place for Canada, China, Korea and European countries Can-Fite BioPharma Ltd. (NYSE:CANF)

  22. Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

    Topline results from NASH Phase II study expected Q1 2020 Namodenoson has already been out-licensed for NASH in China and South Korea Namodenoson article on NASH recently published in International Journal of

  23. Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update

    Reached agreement with U.S. FDA on Phase III liver cancer study design & initiated compassionate use program in Israel Signed new distribution deal for Piclidenoson in South Korea Entered into strategic

  24. Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019

    Can-Fite BioPharma Ltd. (NYSE:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will

  25. Can-Fite Granted Patents for its Sexual Dysfunction Drug

    The drug's unique mechanism of action will allow potential treatment in diabetic patients Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs

  26. Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market

    Company currently evaluating potential partnerships with animal health pharmaceutical companies Treatment of arthritis in canines is an estimated $1.9 billion annual market with unmet need for safe and effective oral

  27. Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients

    Based on encouraging Phase II results, patients with underlying CPB7 cirrhosis who lack a viable treatment option are now provided Namodenoson The Company recently completed a successful End-of-Phase II meeting with

  28. U.S. FDA Agreed with Can-Fite's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer

    Successful conclusion of an End of Phase II meeting with the FDA Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver

  29. Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™

    Topline results expected Q1 2020 Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases,

  30. Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine

    In pre-clinical studies Namodenoson™ significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a

  31. Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference

     International Liver Cancer Association (ILCA) is devoted exclusively to liver cancer research A Phase III study protocol for Namodenoson in the treatment of advanced liver cancer CPB7 patients has been developed

  32. Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

    Cannabinoids bind to A3AR, the target of Can-Fite's drugs Can-Fite's unparalleled expertise in these targets will be utilized to develop new cannabis-based pharmaceuticals The transaction involves technology

  33. Can-Fite to Present at H. C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

    Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and

  34. Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update

     Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up to $10 million plus transfer pricing Preparatory work for an End of Phase II